肥胖相关性肾病诊疗研究进展  

Advances in diagnosis and treatment of obesity-related glomerulopathy

作　　者：邹佳 龚雨顺 罗姣姣 陈愔音[1] Zou Jia;Gong Yu-shun;Luo Jiao-Jiao;Chen Yin-Yin(Department of Nephrology,Hunan Provincial People's Hospital,The First Affiliated Hospital of Hunan Normal University,Changsha,Hunan 410005,China)

机构地区：[1]湖南省人民医院(湖南师范大学附属第一医院)肾内科,湖南长沙410005

出　　处：《中国现代医学杂志》2023年第9期58-63,共6页China Journal of Modern Medicine

基　　金：湖南省重点研发计划项目(No:2020SK2116);湖南省杰青项目(No:2020JJ2020);湖南省卫健委重点项目(No:202203052969)。

摘　　要：肥胖相关性肾病已呈流行发展趋势,已成为终末期肾病的主要原因之一。目前认为其发病机制主要与肥胖所致肾小球血流动力学改变和脂质异位沉积等相关,但其机制仍未完全阐明。减轻体重是治疗肥胖相关性肾病的重要方法,但常因环境、个人执行情况的影响而收效甚微,且有部分患者体重控制后肾病仍持续进展。综合应用有效的肥胖相关性肾病治疗方法,对控制其进展十分重要。该文综述肥胖相关性肾病的致病机制和诊疗进展,探讨中药在肥胖相关性肾病治疗中的价值,旨在为临床提供参考,提高肥胖相关性肾病一体化管理水平。Obbesity related glomerulopathy(ORG)has highlighted an epidemic trend and has become one of the leading causes of end-stage renal disease,having increased twofold in the last decade.The pathogenesis is now thought to be mainly related to obesity-induced alterations in glomerular haemodynamics and ectopic deposition of lipids,but remains incompletely elucidated.Weight loss is an important aspect of treatment for obesity-related glomerulopathy,but it often has little effect due to the environment and individual performance,and in some patients nephropathy continues to progress despite weight control,so a combination of effective ORG treatments is important to control ORG progression.This article reviews the pathogenic mechanisms and therapeutic advances in the treatment of obesity-related glomerulopathy and discusses the value of Chinese medicine in the treatment of ORG,aiming to provide a clinical reference and improve the integrated management of ORG.

关 键 词：肥胖相关性肾病 肥胖 肾素-血管紧张素醛固酮系统抑制剂 降糖药物 中药 

分 类 号：R692[医药卫生—泌尿科学]